This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PMD Psychemedics (PMD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Psychemedics Stock (NASDAQ:PMD) 30 days 90 days 365 days Advanced Chart Get Psychemedics alerts:Sign Up Key Stats Today's Range$2.46▼$2.7750-Day Range$2.32▼$3.2152-Week Range$1.50▼$3.25Volume113,627 shsAverage Volume34,872 shsMarket Capitalization$16.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas. Read More Receive PMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter. Email Address PMD Stock News HeadlinesPsychemedics Releases 2025 Workforce Insights ReportJune 16, 2025 | globenewswire.comPsychemedics Named “Most Innovative Drug Testing Company of the Year”May 16, 2025 | globenewswire.comHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning. | Timothy Sykes (Ad)Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing InsightsMarch 3, 2025 | markets.businessinsider.comPsychemedics announces reverse stock split, forward stock splitDecember 3, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | gurufocus.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | globenewswire.comPsychemedics reminds stockholders to cast votes for Annual MeetingNovember 19, 2024 | markets.businessinsider.comSee More Headlines PMD Stock Analysis - Frequently Asked Questions How were Psychemedics' earnings last quarter? Psychemedics Corporation (NASDAQ:PMD) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business earned $5.20 million during the quarter. Psychemedics had a negative net margin of 9.26% and a negative trailing twelve-month return on equity of 32.32%. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psychemedics investors own include Pfizer (PFE), NVIDIA (NVDA), DraftKings (DKNG), UnitedHealth Group (UNH), Canopy Growth (CGC), Advanced Micro Devices (AMD) and McDonald's (MCD). Company Calendar Last Earnings11/12/2024Today7/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryHealthcare Current SymbolNASDAQ:PMD CIK806517 Webwww.psychemedics.com Phone(978) 206-8220Fax978-264-9236Employees140Year Founded1985Profitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.86 million Net Margins-9.26% Pretax Margin-9.73% Return on Equity-32.32% Return on Assets-18.53% Debt Debt-to-Equity Ratio0.01 Current Ratio1.82 Quick Ratio1.82 Sales & Book Value Annual Sales$19.68 million Price / Sales0.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book3.18Miscellaneous Outstanding Shares6,110,000Free Float5,256,000Market Cap$16.31 million OptionableNot Optionable BetaN/A Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:PMD) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psychemedics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Psychemedics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.